세계 보조생식술(ART) 시장 규모는 2024년 313억 6,000만 달러에서 2032년 561억 7,000만 달러로 2025-2032년 예측 기간 동안 CAGR 7.56%로 성장할 것으로 예상됩니다. 시장 확대는 전 세계 여러 지역의 불임 증가, ART에 대한 투자 증가, 다양한 생식 솔루션의 가용성에 대한 인식 확대, ART에 대한 인식과 접근성을 높이기 위한 정부의 노력 증가에 의해 뒷받침되고 있습니다. 세계보건기구(WHO)는 전 세계 성인 인구의 약 17.5%가 불임을 경험하고 있는 것으로 추정하고 있습니다.
불임의 비율 증가, ART 치료법의 급속한 발전, 다양한 생식 솔루션에 대한 인식의 확대로 인해 시장은 지난 기간 동안 크게 성장했으며, 예측 기간에도 비슷한 결과를 가져올 것으로 예상됩니다. 라이프스타일의 변화, 출산 지연, 다낭성난소증후군(PCOS) 및 자궁내막증과 같은 건강 상태의 유병률 증가 등으로 인해 전 세계적으로 불임 문제에 직면하는 부부가 증가함에 따라 이러한 서비스에 대한 수요가 증가하고 있습니다.
세계의 보조생식술(ART) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 개요 등의 정보를 전해드립니다.
Global assisted reproductive technology (ART) market is projected to witness a CAGR of 7.56% during the forecast period 2025-2032, growing from USD 31.36 billion in 2024 to USD 56.17 billion in 2032. The market's expansion is supported by the increasing incidences of infertility in different regions across the globe, rising investments in ART, growing awareness about the availability of different reproductive solutions, and increasing government initiatives to boost awareness and accessibility of ART. The World Health Organization (WHO) estimates that approximately 17.5% of the adult population across the globe are experiencing infertility.
The market has grown significantly over the historic period and is expected to generate similar results over the forecast period due to increasing rates of infertility, rapid advancements in ART procedures, and growing awareness about different reproductive solutions. The demand for these services has been growing as more couples across the globe face fertility challenges due to lifestyle changes, delayed childbearing, and increasing prevalence of health conditions such as polycystic ovary syndrome (PCOS) and endometriosis.
Technological Advancements Drive Market Growth
Leading fertility providers across the globe are focusing on developing and introducing advanced reproductive technologies, propelling the market's expansion. Advancements in artificial intelligence, micromanipulators, time-lapse imaging systems, and advanced incubators improve the success rate and precision of intracytoplasmic sperm injections and in-vitro fertilization. Artificial intelligence (AI) powered tools assist clinicians in embryo selection, medication dosing, and streamlining clinical operations. Thus, various companies are increasingly focusing on investing in such technologies. For instance, in March 2024, Alife Health partnered with Boston IVF, LLC, to pilot the first AI tools in the United States for IVF medication optimization. The latter is implementing Alife's Stim Assist software, designed for aiding IVF clinicians in retrieving the optimal number of eggs for improved success rate of the procedure.
Rising Government Efforts Support Market Expansion
Increasing efforts by various governments to boost population growth and increase awareness and accessibility to ART services are among the major factors driving the market's growth. Most countries are considering introducing supportive policies and subsidized funding schemes in order to bolster population growth and address infertility. Additionally, national guidelines such as those in France, Germany, and Australia have provided an ethical-legal standardization for ART procedure supervision and patient safety. Moreover, rising research grants and funds for fertility science are fostering technological advancements to increase the accessibility of effective treatments.
Meanwhile, countries with declining birth rates are introducing various policies to encourage family planning, which are expected to drive the market's demand. For instance, the Tokyo Metropolitan Government plans on implementing a four-day workweek from April 2025, to improve workplace flexibility and allow parents to balance family responsibilities.
Fertility Clinics Account for Significant Share of the Market
The high popularity of fertility clinics for availing ART services can be attributed to the comprehensive range of procedures and customized treatment plans offered to the patients. Most of these clinics provide a full spectrum of procedures such as preimplantation genetic testing, sperm and egg freezing, intrauterine insemination, and in-vitro fertilization, among others. Additionally, these clinics are also equipped with advanced technological solutions and infrastructure, as well as skilled medical professionals and counsellors, ensuring higher success rates and improved patient satisfaction.
Furthermore, leading fertility clinics are investing in their expansion and focusing on providing services in previously underserved regions, further supporting the segment's growth and expansion. For instance, in February 2025, Wellnest Fertility Inc. launched the Wellnest Fertility Clinic in Utah, United States, introducing a state-of-the-art facility that delivers comprehensive fertility care with personalized treatment plans and advanced embryo monitoring technology. By incorporating continuous, time-lapse embryo monitoring, the clinic enables embryologists to observe embryo development in real time without disturbing their environment, providing invaluable insights into growth patterns and key developmental milestones. This technology enhances the precision of embryo selection, increases the likelihood of successful pregnancies, and ultimately improves patient outcomes. The expansion of such innovative services by fertility clinics worldwide is expected to boost patient confidence in fertility treatments, reduce geographical barriers to high-quality care, and create significant growth opportunities within the ART market.
Europe Holds Major Market Share
The region's dominance can be attributed to the increasing prevalence of infertility in Europe due to evolving societal norms and delayed childbearing, widespread availability of fertility services, and the presence of favorable legislation and regulations in countries such as the United Kingdom, France, and Belgium. These countries also have generous reimbursement policies, reducing out-of-pocket expenses for the patient population. Furthermore, Europe is also a hub for medical tourism in reproductive health, providing relief from higher treatment costs and restrictive laws. The easy availability and adoption of advanced technologies, including single embryo transfer and preimplantation genetic testing, are bolstering the success rate of ART, further augmenting the market's expansion. Furthermore, Europe estimates that approximately 25 million people in the European Union are affected by infertility.
Meanwhile, the market in North America is expected to witness significant growth in the coming years due to the increasing number of same-sex couples in the country, the availability and acceptance of advanced technologies, and the increasing popularity of single parenthood.
Impact of U.S. Tariffs on Global Assisted Reproductive Technology (ART) Market
These tariffs are expected to affect a significant portion of the medical device industry and influence various facets of the ART market, including international trade dynamics and production costs. Tariffs are also expected to potentially disrupt supply chains, forcing companies to relocate manufacturing processes and seek alternative suppliers, which may not be entirely feasible due to the existing regulatory and infrastructural requirements.
Moreover, manufacturers in the United States might find it challenging to compete internationally if other countries retaliate by introducing their own tariffs, resulting in market fragmentation. Thus, stakeholders in the industry will need to navigate the shift in trade dynamics and increase production costs to adapt and hold their position in the market.
Key Players Landscape and Outlook
In order to improve the treatment outcomes and aid researchers and scientists in advancing reproductive technologies, the key players of the market are focusing on new products. For instance, in July 2023, Thermo Fisher Scientific Inc. launched the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit for preimplantation genetic testing-aneuploidy (PGT-A). PGT-A is used to identify chromosomal abnormalities in embryos, allowing clinicians to select the most viable embryos for implantation and improving the success rate of the process. Such launches also provide deeper genomic insights to reproductive researchers, improving reproductive health outcomes and the success rate of pregnancies.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.